Background: Alterations in bone mineral density (BMD) in patients with psychotic disorder may reflect the effect of treatment (disease effect observed in patients but not their siblings) or, as an intermediate marker of cumulative endogenous estrogen exposure, alterations in the neuroprotective effect of estrogen in the brain (vulnerability effect observed in patients and siblings). Methods: Dual X-ray absorptiometry (DEXA) scans were acquired in 62 patients with a psychotic disorder, 67 non-psychotic siblings of patients with a psychotic disorder, and 48 controls. BMD (g/cm 2 ), Z-scores and T-scores were measured in the lumbar spine and proximal femur. Associations between group and BMD were investigated with multilevel random regression analyses. Group × sex interactions and effects of antipsychotic medication (AP) on BMD were examined. Results: Group was not associated with BMD outcome measures, although patients had consistently lower BMD measures compared to both siblings and controls. There were no significant group × sex interactions, but stratified analyses showed that BMD measures in female patients were significantly lower in comparison to female controls and siblings (e.g. total femoral BMD, P vs. C: B = − 0.100, p = 0.010; P vs. S: B = − 0.104, p =0.008). After excluding female patients who used prolactin-raising AP, the effect was attenuated (e.g. total femoral BMD, P vs. C: B =−0.073, p=0.072; P vs. S: B =−0.085, p =0.051). In men, there were no significant BMD differences between patients and controls. Conclusion: Familial risk of psychotic disorder was not associated with BMD. Instead, decreased BMD in the femur may reflect treatment effects or non-familial risk associated with low cumulative endogenous estrogen levels in women.
Introduction
In the past decade, an increased awareness of compromised skeletal status in patients with psychotic disorder has developed. This is based on findings of reduced bone mineral density (BMD) in this population, possibly resulting from a high prevalence of risk factors for osteoporosis (Haddad and Wieck, 2004; Halbreich, 2007) . Some risk factors for osteoporosis may be inherent to positive and negative symptomatology such as polydipsia (Delva et al., 1989) , diminished dietary intake, decreased physical activity and reduced sunlight exposure. In addition, comorbid substance abuse may further influence vulnerability for osteoporosis, as alcohol and cannabis have been shown to affect bone metabolism (Bab et al., 2009; Maurel et al., 2012) . Hyperprolactinemia-induced hypogonadism, secondary to treatment with potent dopamine-2 receptor antagonists, has also been proposed as a factor contributing to loss of bone mass in schizophrenia (Bilici et al., 2002; Abraham et al., 2003a; Meaney et al., 2004; Meaney and O'Keane, 2007; Kishimoto et al., 2008) . Notably, not all studies have found evidence for BMD reduction in patients (Howes et al., 2005) , or for an effect of prolactin-raising antipsychotic drugs (AP) on BMD Renn et al., 2010) .
While there is evidence for decreased BMD specifically in male patients with schizophrenia (Hummer et al., 2005; Lehman and Meyer, 2005; Meyer and Lehman, 2006; Kishimoto et al., 2008) , there are also studies suggesting that female patients are particularly vulnerable to compromised skeletal status (Partti et al., 2010) , with some evidence for higher bone turnover, but normal bone mineral density (Abraham et al., 2003b; Bergemann et al., 2008) .
The above mentioned studies (all cross-sectional, with the exception of two (Abraham et al., 2003b; Meaney and O'Keane, 2007) ), differ with respect to cohort characteristics (e.g. sample size, stage of illness, male and/or female participants, women in pre-or postmenopausal phase) and correction for confounding factors, which may have contributed to an inconsistent pattern of results. Nevertheless, most studies are suggestive of reduced BMD in schizophrenia.
Loss of BMD may be a consequence of psychotic disorder or its treatment, but an alternative hypothesis is that a reduction in BMD, as a marker of cumulative endogenous estrogen exposure (Clemons and Goss, 2001) , is an indicator of risk for and development of psychotic disorder (due to diminished neuroprotection of estrogen in the brain) (Maric et al., 2005) . A primary low endogenous estrogen level may be associated with genetic risk of the disorder (intermediate phenotype) or, alternatively, represent a non-familial marker of risk.
The aim of the present study was to examine BMD in subjects at high genetic risk of psychotic disorder (patients with psychotic disorder) and subjects at higher than average genetic risk (unaffected siblings of patients with psychotic disorder) in comparison with individuals at average genetic risk of psychotic disorder (healthy controls). We hypothesized that BMD, as a marker of cumulative endogenous estrogen exposure, would be reduced in both patients and siblings, reflecting shared familial liability. The objective was not to identify a large, clinically relevant decline in BMD (e.g. to be able to pinpoint and reduce fracture risk), but to discern a difference, even small, that may be related to the (familial) etiology of schizophrenia and other psychotic disorders.
Materials and methods

Subjects
Data was collected in the context of an ongoing longitudinal study in Maastricht, The Netherlands (Habets et al., 2011; Korver et al., 2012) . In selected representative geographic areas in The Netherlands and Belgium, patients presenting consecutively at mental health services either as outpatients or inpatients were recruited for the study. Siblings were sampled through participating patients. Control subjects were recruited from the same population as the cases using random mailings in nearby municipalities and through advertisement in newspapers. Patients between the ages of 16 and 50 years with a diagnosis of non-organic, non-affective psychosis were included. Sufficient command of the Dutch language was an additional criterion for inclusion. Diagnosis was based on DSM-IV criteria (APA, 2000) , assessed with the Comprehensive Assessment of Symptoms and History (CASH) interview (Andreasen et al., 1992) . The CASH was also used to confirm the absence of a diagnosis of non-affective psychosis in the siblings, and absence of a diagnosis of any psychotic disorder in the control subjects. For the control subjects, the occurrence of any psychotic disorder in either the subject or any first-degree family member, assessed using the Family Interview for Genetic Studies, constituted an exclusion criterion.
The sample consisted of 62 patients with a psychotic disorder (of whom 50 patients had a diagnosis of schizophrenia, 4 patients had a diagnosis of schizoaffective disorder, 7 patients had a diagnosis of psychotic disorder not otherwise specified and 1 patient had a diagnosis of brief psychotic disorder), 67 non-psychotic siblings and 48 controls. The sample included 36 families, of which 24 families contributed one patient and one sibling and two families contributed one patient and 2 siblings. One family contributed two patients and one sibling; in one family one patient and 3 siblings participated. Two families contributed two siblings but no patients. In the control group, six families contributed two siblings. Thirty-three independent patients, 31 independent siblings, and 36 independent controls participated.
Nine controls and sixteen siblings had a history of major depressive disorder (MDD). In addition, one sibling was diagnosed with dysthymic disorder and one with mood disorder due to a general medical condition.
Prior to DEXA acquisition, participants were screened for the following exclusion criteria: 1) metabolic or endocrinologic disease, 2) dietary deficiency or eating disorder, 3) medication use: corticosteroids, thyroxin, anti-epileptics, heparin, lithium, cytostatic agents, 4) (semi-)professional athletes, 5) polydipsia (>3 l/day), 6) pregnancy, and 7) hormonal (infertility) treatment.
Measures
Substance use
Substance use was assessed using the Composite International Diagnostic Interview (CIDI) (WHO, 1990) . Cannabis use was assessed as reported lifetime frequency of use. Other drug use, such as stimulants, sedatives, opiates, cocaine, PCP, psychedelics, inhalants or other (e.g. ecstasy, poppers) was assessed in the same way. Alcohol use was defined as the average number of weekly instances of consumption during the previous 12 months. Tobacco use was defined as the number of cigarettes, cigars or pipes per day, or number of daily occasions of use of chewing tobacco or snuff.
Physical activity and sunlight exposure
Physical activity and sunlight exposure were expressed in total minutes per week.
To quantify physical activity, the total amount of time spent on commuting by foot or bicycle, physical activity at work or school, household chores, active hobbies and sports was summed. Sunlight exposure was calculated by multiplying the number of days per week a person went outside by the average number of minutes spent outside on those days.
AP use
Current AP use was classified by AP type: "prolactin-raising", i.e. first-generation APs, risperidone and amisulpride; or "prolactinsparing", i.e. second or third-generation APs with the exception of risperidone and amisulpride.
Use of contraceptive drugs (cumulative exogenous estrogen exposure)
Cumulative exogenous estrogen exposure in women was determined by multiplying the daily dose with the total days of use, expressed in micrograms.
Age at menarche and dysmenorrhea
Age at menarche and the occurrence of menstrual irregularity were assessed in women. Dysmenorrhea was defined as altered duration and/or frequency of menses or the absence of two or more menses during the previous three months. Amenorrhea was defined as the absence of menses for at least three months.
Familial osteoporosis
The occurrence of familial osteoporosis was documented.
DEXA acquisition and processing
DEXA scans were acquired at the Maastricht University Medical Center with a Hologic Discovery A (Tromp Medical, Castricum, The Netherlands) (NHANES and Ethnic Reference Data). DEXA scans of two anatomical areas were performed: the lumbar spine, vertebrae L2 through L4; and the proximal left femur, specifically the collum, trochanter major, intertrochanteric area and Ward's triangle. BMD was expressed in grams per square centimeter (g/cm 2 ), Z-scores and T-scores. The Z-score compares an individual's BMD with the mean BMD of a comparable population (with respect to gender, age and ethnicity). The T-score compares an individual's BMD to peak bone mass (PBM). Peak bone mass is the highest BMD an individual is expected to acquire during life. The T-score is used to diagnose osteopenia and osteoporosis. The World Health Organization employs the following criteria: T-scores in osteopenia lie between − 1.0 and − 2.5; T-scores in osteoporosis are equal or less than − 2.5. This study was approved by the standing ethics committee. All subjects provided written informed consent in accordance with the committee's guidelines.
Statistical analyses
Group differences in total BMD, Z-scores and T-scores were analyzed separately for the lumbar spine and proximal femur. Multilevel random regression models were fitted (Goldstein, 1987) given hierarchical clustering occasioned by the fact that participants were clustered in families, compromising statistical independence of the observations. This was done using the XTREG command in STATA (STATA Corp., version 11). BMD measures were the dependent variables in the analyses and group (entered both as linear and dummy variables (controls = 0, siblings = 1 and patients = 2)) was the independent variable. Analyses were adjusted for a priori hypothesized confounders: cumulative exogenous estrogen exposure, gender, age, BMI, physical activity, sunlight exposure, tobacco and alcohol use, and lifetime exposure to cannabis.
To test whether BMD measures were not only conditional on group but also on sex, group× sex interactions were examined. In addition, a priori stratified analyses for males and females were conducted separately, given strong physiological sex differences in bone metabolism, possibly violating assumptions of underlying homogeneity in mechanisms and associations. Group× sex interaction terms were evaluated by Wald test (Clayton and Hills, 1993) . In the analyses stratified by sex, age at menarche and menstrual irregularity were additional covariates in the model of women.
The study population included nine control subjects and eighteen siblings with a history of affective disorder. Conceptually, these individuals may be at risk of decreased BMD due to factors also associated with psychotic disorder, such as inactivity and diminished sunlight exposure. In addition, selective serotonin reuptake inhibitors (SSRIs) potentially reduce BMD (Halbreich, 2007) . Therefore, planned sensitivity analyses were conducted excluding these individuals.
Main effects of current type of AP exposure on BMD in patients were examined by comparing prolactin-sparing and prolactin-raising APs to no AP (dummy variable: no AP = 0, prolactin-raising = 1, prolactin-sparing = 2) using multiple regression procedures; with sex, age and BMI as potential confounders. Planned sensitivity analyses were performed excluding patients who used a prolactin-raising AP.
To control for a type I error, all significant p-values were subjected to correction for multiple testing using the Simes method (Simes, 1986; Rodland, 2006) . The Simes method avoids overcorrection associated with the Bonferroni correction in case the statistical tests are not independent, as was the case in the present study (BMD measures are correlated with each other). p-Values were ranked and Simes p-values were calculated as j * alpha / k, where k is the number of p-values in the ranking and j is the ranking of that p-value. The adjusted p-value is that of the lowest ranking for which p b p adjusted (hereafter: p Simes ).
Results
Descriptive analyses
There were more female participants in the control group and more males in the patient group. Controls were slightly older than patients and siblings. Patients used more tobacco, as well as more cannabis and other drugs, compared to controls and siblings. Siblings used more cannabis than controls. Among women, patients experienced more menstrual irregularities than siblings and controls ( Table 1) .
Out of 62 patients, 56 currently used AP medication, of whom 28 were prescribed prolactin-raising agents (3 patients used haloperidol, 1 zuclopenthixol, 17 risperidone and 7 amisulpride; of the latter 1 patient used a combination of amisulpride and aripiprazole, 1 used a combination of amisulpride and haloperidol and 1 patient used a combination of amisulpride and risperidone). Several patients used psychotropic medication other than an AP: twelve used antidepressants (of which 11 used a SSRI or serotonin and noradrenalin reuptake inhibitor (SNRI), and 1 used trazodone), three used benzodiazepines, two used anticholinergic agents, and there was one occasion of stimulant (methylphenidate) use. Two control subjects used an SSRI. None of the siblings used psychotropic medication.
Mean BMD measures and prevalence of osteopenia/osteoporosis
The raw data showed that mean BMD measures in patients were lower than those in siblings and controls. Siblings had consistently lower mean BMD measures than controls in the lumbar spine, but not the femur. Compared to controls, the proportion of osteopenia and osteoporosis cases in the group of patients and siblings was larger, albeit not statistically significant (Table 2) .
Associations between group and BMD measures of the lumbar spine and femur
There was no statistically significant association between group (linear trend) and BMD, although effect sizes were negative for all six BMD measures. In the patient-control comparison, the direction of the effect size was consistently negative for all six BMD measures of the lumbar spine and femur, but did not reach significance. Similarly, there were no significant findings in the sibling-control comparison.
Comparing patients to siblings, there was a negative association for all BMD measures. The reduction in total BMD and Z-score of the femur was significant (B=−0.061, 95% CI: −0.117 to −0.005, p=0.033; and B=−0.414, 95% CI: −0.827 to −0.001, p=0.050 respectively), though not after Simes correction. The reduction of the femoral T-score did not reach significance (B=−0.384, 95% CI: −0.797 to 0.030, p=0.069) ( Table 3) .
Group × sex interaction and stratified analyses by sex
There were no significant group × sex interactions for the lumbar spine or proximal femur.
In women, all BMD measures of the femur were significantly reduced in patients compared to controls and siblings, with no significant differences between siblings and controls. These findings held after Simes correction (p Simes : pb 0.017).
In men, no significant associations were found between BMD and group. The direction of the effect was generally positive in the lumbar spine, but consistently negative in the femur in male patients and siblings compared to controls (Table 4) .
Associations between antipsychotic medication and BMD
In the total patient group, no significant associations between the type of current AP and BMD were found, when compared to AP-free patients. In women, but not in men, the current use of a prolactin-raising AP (n=6) appeared to be negatively associated with BMD measures of the lumbar spine, when compared to AP-free female patients (n=3) (total BMD: B=−0.113, 95% CI: −0.220 to −0.006, p=0.041; Z-score: B=−1.109, 95% CI: −2.243 to 0.025, p=0.054; T-score: B=−1.199, 95% CI: −2.236 to −0.162, p=0.027). Results were not upheld after Simes correction. No such association was found for the femur.
Exclusion of affective disorder and prolactin-raising AP
Repeating the analyses excluding siblings and controls with a history of affective disorder did not affect the findings in the total group (n= 150), or in men (n=87), and thus remained negative. In women (n= 63), the significance level of the negative association between group (patients) and femoral BMD was enhanced (see effect sizes and p-values in Fig. 1 ). These findings held after Simes correction (p Simes : pb 0.017).
In addition, a negative association in the lumbar spine became apparent in the patient versus control comparison, although this was not upheld after Simes correction (patients versus controls, total BMD: B=−0.079, 95% CI: −0.171 to 0.013, p = 0.093; Z-score: B = −0.888, 95% CI −1.756 to−0.021, p = 0.045; T-score: B =−0.839, 95% CI −1.672 to −0.005, p =0.049). Female siblings were not significantly different from female controls or patients for all BMD measures.
Analyses were once again repeated after excluding the six female patients who used a prolactin-raising AP. Ten female patients remained in the sample. Femoral BMD remained decreased in patients compared to siblings at a trend-level of significance (total BMD: B = −0.085, 95% CI −0.171 to 0.000, p = 0.051; Z-score: B = −0.748, 95% CI −1.484 to −0.011, p = 0.047; T-score: B = −0.708, 95% CI −1.437 to 0.021, p = 0.057), although effect sizes decreased with 23%, 24% and 26% respectively. The reduction in BMD in patients compared to controls was no longer significant (total BMD: B = −0.073, 95% CI: −0.152 to 0.006, p = 0.072; Z-score: B = −0.630, 95% CI −1.313 to 0.054, p = 0.071; T-score: B = −0.592, 95% CI −1.268 to 0.084, p = 0.086), as effect sizes decreased with respectively 31%, 32% and 34% (Fig. 1) .
Discussion
This study examined BMD as a potential biological marker of cumulative endogenous estrogen exposure in patients with a psychotic disorder, non-psychotic siblings of patients with a psychotic disorder and controls. In the entire sample, group was not conclusively associated with BMD outcome measures, however BMD was directionally lower in patients compared to controls and siblings. Significantly decreased BMD was found specifically in the femur of female patients. After exclusion of patients with prolactin-raising AP, the reduction in femoral BMD was attenuated.
Findings
Total group (men and women)
Contrary to the initial hypothesis, individuals at higher than average and highest genetic risk for psychotic disorder did not have significantly decreased BMD measures compared to controls. Although patients showed consistently lower BMD measures than controls and siblings, the associations were statistically inconclusive or reached trend-level significance. While most previous studies are indicative of reduced BMD in schizophrenia, some (Howes et al., 2005) did not find a significant reduction in BMD in patients with schizophrenia.
Siblings were not statistically different from controls, indicating that reduced cumulative endogenous estrogen exposure is not a marker of shared familial risk for psychotic disorder.
Sex-specific findings
All BMD measures in the femurs of female patients were significantly lower than female controls and siblings. This is in accordance with earlier findings that identified women with schizophrenia as a population that is vulnerable for reduced BMD (Meaney and O'Keane, 2007) . However, the reduction in femoral BMD was less pronounced and with reduced significance levels (up to p = 0.086) after excluding patients with prolactin-raising AP, suggesting a negative effect of prolactin-raising AP on BMD or lack of power (see below). In addition, there was no main effect of prolactin-raising AP on femoral BMD, whereas such an effect was apparent for lumbar BMD.
A population-based study concluded that schizophrenia may be an independent determinant of poor skeletal status in women, after adjusting for AP use (among other factors) (Partti et al., 2010) . Maric et al. (2005) examined BMD in the lumbar spine of 19 female patients presenting with a first episode of psychosis and healthy female controls. They found that patients had amassed significantly less bone mass than healthy controls. The femur was not examined in this study. In their sample, exposure to AP was minimal and risk factors for osteoporosis secondary to the disease status of psychotic disorder are likely less prominent in individuals presenting with a first episode of psychosis. Our findings in 16 female patients also indicated a reduction in BMD in the femur as well as in the lumbar spine (only after exclusion of affective disorder). Thus, similar to Maric et al. (2005) , we cautiously suggest that, to the degree that BMD is a biological marker of cumulative endogenous estrogen exposure, reduced BMD may reflect diminished estrogen-induced neuroprotection and synaptic plasticity which, in turn, may place women at risk of developing a psychotic disorder. However, since this risk was not shared with siblings, it likely reflects a unique environmental experience associated with lifestyle, exogenous exposures or stochastic mechanisms. Nevertheless, if a primary role for estrogen exists, the findings indicate that it does not exclude an additional effect of prolactin-raising APs on BMD (see below under Antipsychotic medication). In contrast to our findings in women, no association between psychotic disorder and BMD was revealed in men. Theoretically, the effects of estrogen on both brain and bone are not specific to women: androgens are aromatized focally and reach biologically effective concentrations at these tissue sites in men (Boerma et al., 2010) . In support of this, beneficial effects of estrogen and its receptor modulators as adjunctive therapy for psychosis have been reported in both sexes (Kulkarni et al., 2008 (Kulkarni et al., , 2010 (Kulkarni et al., , 2011 . However, in men, the availability of endogenous estrogen is entirely dependent on aromatase. Possibly, the expression and/or activity of aromatase in the brain is altered in disease states (Melcangi et al., 2011) . For example, if psychotic disorder should lead to altered function of aromatase specifically in the male brain (but not in bone), cerebral estrogen levels will be low while BMD remains unaffected. If this were true, the use of BMD as an indirect marker of cerebral estrogen exposure would not be informative. In women, neuroprotective effects of estrogen may be enhanced by cyclic availability of endogenous progesterone (Azcoitia et al., 2011) . Due to dysmenorrhea, women with psychotic disorder may not benefit from the synergy of both hormones, thereby enlarging the difference between groups. This lends plausibility to the hypothesis that sexspecific (patho)physiological mechanisms related to the disease state may operate.
An alternative explanation for our inconclusive findings in men may be found in the sample characteristics. The mean BMD measures of 13 male controls were rather low. Z-scores in the control group were expected to be approximately zero, as this represents the mean in the general population (corrected for sex, age and ethnicity). However, in the present sample, the mean lumbar Z-score was negative in male controls. In addition, all mean BMD measures of both the lumbar spine and the femur were lower in male controls than in male siblings. This may have potentially masked a true association in men and in the total group.
Antipsychotic medication
A significant association between prolactin-raising AP and BMD was found in women, but not in men. More specifically, the current use of a prolactin-raising AP was negatively associated with BMD in the lumbar spine of female patients (though not after Simes correction) . This is of interest, as our findings of reduced BMD in female patients were present in the femur, but not the lumbar spine. In the literature, there is a large body of work reporting significant negative associations between first-generation AP and BMD (Bilici et al., 2002; Meaney et al., 2004; Howard et al., 2007; Kishimoto et al., 2008) . Conversely, several other studies failed to discover an association between BMD and APs (Howes et al., 2005; Hummer et al., 2005; Lee et al., 2010; Renn et al., 2010) . Women have been described as particularly prone to AP-induced hyperprolactinemia (Smith et al., 2002; Kinon et al., 2003) , although the biological substrate remains unclear. Pharmacokinetic factors, such as a higher proportion of body fat and increased cerebral blood flow that have been proposed to underlie the better treatment response to AP in women (Kolsch and Rao, 2002) , may operate. Because there was a loss of effect size and statistical significance when women with prolactin-raising AP were excluded, we cannot exclude the possibility of a sex-specific susceptibility to AP-induced hyperprolactinemia in women as partial explanation for the findings. At the same time, this analysis resulted in a 37.5% reduction in sample size and thus low statistical power to detect BMD differences at conventional alpha-level. A meta-analysis of the effects of AP on BMD has not been published but is warranted, considering the contradictory results in this clinically important matter.
Methodological considerations
The sample size was not particularly large. A group × sex interaction was possibly not found due to an unbalanced sex distribution over the relatively small groups in combination with low mean BMD values in male controls. Thus, whether tests for interaction lacked power because of the small proportion of males in the control group, or whether there is simply no effect of group conditional on gender, remains to be elucidated in future studies. Nevertheless, all results from models restricted to the female part of the sample were upheld after Simes correction ( Fig. 1 and Table 4), with the exception of the repeated analyses in the smallest subgroup (exclusion of both siblings and controls with a history of affective disorder and patients with a prolactin-raising AP). It is debatable whether correction for multiple testing is appropriate in the present study. Six out of eighteen comparisons in women rendered significant findings. Given that the probability of a type I error is only 5%, the number of positive findings markedly exceeds the number of false-positive findings that would have been expected by chance alone. In summary, lack of power does not preclude detection of positive findings, as shown in the present study, but the inconclusive findings need replication in a larger population, before definite conclusions can be reached.
Although BMD is an indirect measure of endogenous estrogen exposure, a clear advantage of BMD is that it reflects cumulative lifetime exposure, while the direct measurement of estrogen in serum or urine is a momentary assessment of estrogen levels. The latter would have been less informative regarding the research question under study. Nevertheless, hormone levels associated with the hypothalamuspituitary-gonadal axis could have aided in excluding (peri)menopausal state in female patients, although subjective reports were negative and, in combination with the age range (17-43 years), it is unlikely that our findings, in whole or in part, can be ascribed to loss of BMD secondary to menopause. Moreover, analyses were adjusted for menstrual irregularities.
The present sample is representative of the total (patient) population in our area, and confounders were corrected for. With regard to substance abuse, analyses were adjusted for the a priori hypothesized confounders of alcohol, tobacco and cannabis use. There is little evidence for an association between other (non-cannabis) drugs and BMD. In our data, there was no significant main effect of other drugs on BMD. In addition, adjustment for other drug use did not affect the pattern of the findings (results available upon request). Although best estimates of sunlight exposure were quantified, measurement of vitamin D blood levels could have been a useful alternative. In addition, serum prolactin would be a valuable objective measure. Unfortunately, these blood sample measures were not available.
The majority of publications to date focused primarily on the effects of prolactin-raising antipsychotics on BMD. To the best of our knowledge, this is the first study to investigate associations between different levels of familial risk of psychotic disorder and BMD.
Naturally, cross-sectional analyses cannot identify causal relationships. Over the follow-up, all participants have undergone a second DEXA scan. The disease course in patients and the possible transition of healthy siblings to patient status may provide further clues to the potential role of estrogen in the etiology and pathophysiology of psychotic disorders.
Conclusions
There was no evidence for low cumulative endogenous estrogen exposure (as measured by BMD), as an endophenotypic marker for psychotic disorder. BMD reduction was associated with being female and patient, suggesting that unique environmental factors contributing to primary low estrogen levels in women may impact the risk of developing a psychotic disorder, in support of the estrogen hypothesis of schizophrenia. However, gender-specific susceptibility to the effects of prolactin-raising AP on BMD may also operate.
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